Literature DB >> 17371876

Up-regulation of MET expression by alpha-melanocyte-stimulating hormone and MITF allows hepatocyte growth factor to protect melanocytes and melanoma cells from apoptosis.

Laurent Beuret1, Enrica Flori, Christophe Denoyelle, Karine Bille, Roser Busca, Mauro Picardo, Corine Bertolotto, Robert Ballotti.   

Abstract

The MET proto-oncogene encodes for the hepatocyte growth factor (HGF) receptor, a plasma membrane tyrosine kinase that is involved in melanocyte growth and melanoma development. In mouse melanoma cells, Met expression is increased by alphaMSH via the activation of the cAMP pathway. However, the mechanism by which cAMP regulates MET and the biological consequences of this increase were not known. In the present report, we show that alphaMSH regulates MET expression in both human melanocytes and mouse melanoma cells through a transcriptional mechanism that requires MITF. Furthermore, the adenovirus driven expression of MITF is sufficient to increase MET in melanoma cells. Functional analysis of the MET promoter allows us to identify an E-box motif conserved in both human and mouse promoter that mediates the effect of MITF. Interestingly, up-regulation of MET expression by cAMP leads to an exacerbated HGF signaling and allows HGF to protect melanocytes and melanoma cells from apoptosis. Thus, physiological stimuli or pathological events that would induce MITF expression may lead to increased MET expression thereby favoring melanoma survival. These observations strengthen the roles of MITF and MET in melanoma development.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17371876     DOI: 10.1074/jbc.M611563200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  33 in total

1.  HGF-promoted motility in primary human melanocytes depends on CD44v6 regulated via NF-kappa B, Egr-1, and C/EBP-beta.

Authors:  Sabine Damm; Petra Koefinger; Martina Stefan; Christian Wels; Gabor Mehes; Erika Richtig; Helmut Kerl; Marcus Otte; Helmut Schaider
Journal:  J Invest Dermatol       Date:  2010-04-01       Impact factor: 8.551

2.  Absence of germline CDKN2A mutation in Sicilian patients with familial malignant melanoma: Could it be a population-specific genetic signature?

Authors:  Sara Di Lorenzo; Daniele Fanale; Bartolo Corradino; Valentina Caló; Gaetana Rinaldi; Viviana Bazan; Antonio Giordano; Adriana Cordova; Antonio Russo
Journal:  Cancer Biol Ther       Date:  2016       Impact factor: 4.742

3.  Ciglitazone negatively regulates CXCL1 signaling through MITF to suppress melanoma growth.

Authors:  T Botton; A Puissant; Y Cheli; T Tomic; S Giuliano; L Fajas; M Deckert; J-P Ortonne; C Bertolotto; S Tartare-Deckert; R Ballotti; S Rocchi
Journal:  Cell Death Differ       Date:  2010-07-02       Impact factor: 15.828

Review 4.  Pro-survival role of MITF in melanoma.

Authors:  Mariusz L Hartman; Malgorzata Czyz
Journal:  J Invest Dermatol       Date:  2014-08-21       Impact factor: 8.551

5.  Identification of MET and SRC activation in melanoma cell lines showing primary resistance to PLX4032.

Authors:  Elisabetta Vergani; Viviana Vallacchi; Simona Frigerio; Paola Deho; Piera Mondellini; Paola Perego; Giuliana Cassinelli; Cinzia Lanzi; Maria Adele Testi; Licia Rivoltini; Italia Bongarzone; Monica Rodolfo
Journal:  Neoplasia       Date:  2011-12       Impact factor: 5.715

6.  Slug expression during melanoma progression.

Authors:  Stephanie H Shirley; Victoria R Greene; Lyn M Duncan; Carlos A Torres Cabala; Elizabeth A Grimm; Donna F Kusewitt
Journal:  Am J Pathol       Date:  2012-04-13       Impact factor: 4.307

7.  Aurora B is regulated by the mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) signaling pathway and is a valuable potential target in melanoma cells.

Authors:  Caroline Bonet; Sandy Giuliano; Mickaël Ohanna; Karine Bille; Maryline Allegra; Jean-Philippe Lacour; Philippe Bahadoran; Stéphane Rocchi; Robert Ballotti; Corine Bertolotto
Journal:  J Biol Chem       Date:  2012-07-05       Impact factor: 5.157

Review 8.  Malignant melanoma in the 21st century: the emerging molecular landscape.

Authors:  Aleksandar Sekulic; Paul Haluska; Arlo J Miller; Josep Genebriera De Lamo; Samuel Ejadi; Jose S Pulido; Diva R Salomao; Erik C Thorland; Richard G Vile; David L Swanson; Barbara A Pockaj; Susan D Laman; Mark R Pittelkow; Svetomir N Markovic
Journal:  Mayo Clin Proc       Date:  2008-07       Impact factor: 7.616

9.  PAX6 is expressed in pancreatic cancer and actively participates in cancer progression through activation of the MET tyrosine kinase receptor gene.

Authors:  Joseph B Mascarenhas; Kacey P Young; Erica L Littlejohn; Brian K Yoo; Ravi Salgia; Deborah Lang
Journal:  J Biol Chem       Date:  2009-08-03       Impact factor: 5.157

10.  PAX3 and SOX10 activate MET receptor expression in melanoma.

Authors:  Joseph B Mascarenhas; Erica L Littlejohn; Rebecca J Wolsky; Kacey P Young; Maria Nelson; Ravi Salgia; Deborah Lang
Journal:  Pigment Cell Melanoma Res       Date:  2010-01-22       Impact factor: 4.693

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.